These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 4305290

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Primary resistance in adult pulmonary tuberculosis in France. 3d report of the study center on Primary Resistance: 1966-1970].
    Canetti G, Le Lirzin M, Gay P, Thibier R, Kreis B, Grosset J.
    Rev Tuberc Pneumol (Paris); 1972; 36(3):337-56. PubMed ID: 5080965
    [No Abstract] [Full Text] [Related]

  • 24. Drug-resistant pulmonary tuberculosis.
    Kossmann CE.
    J Tenn Med Assoc; 1978 Dec; 71(12):905-7, 909. PubMed ID: 756916
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Therapeutic results in lung diseases caused by atypical mycobacteria].
    Fischer P, Schilling W.
    Z Erkr Atmungsorgane; 1984 Dec; 162(1):26-9. PubMed ID: 6202070
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Effect of vitamins on general condition of the T- and B-immunity systems during antibacterial treatment of pulmonary tuberculosis].
    Volosevich GV.
    Probl Tuberk; 1978 Oct; (10):36-9. PubMed ID: 309606
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Evaluation of the therapeutic effects of secondary antitubercular agents].
    Watanabe S, Nosaki M, Iwasaki M, Hamano S, Furuya Y.
    Iryo; 1966 Mar; 20(3):251-6. PubMed ID: 5965119
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Clinical and bacteriological problems of ethionamide therapy].
    Lányi M.
    Z Tuberk Erkr Thoraxorg; 1965 Jul; 123(4):332-4. PubMed ID: 5897862
    [No Abstract] [Full Text] [Related]

  • 35. [Significance of isoniazid for the therapy of experimental infection with total INH- and SM- resistant human tuberculosis bacteria in the mice].
    Matsumiya T, Freerksen E, Rosenfeld M.
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):14-29. PubMed ID: 4320557
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Duration of the after-control of the tuberculous patients following the termination of the treatment].
    Neumann G.
    Wien Med Wochenschr; 1972 Dec 16; 122(51):764-8. PubMed ID: 4346497
    [No Abstract] [Full Text] [Related]

  • 40. [Controlled intermittent treatment of pulmonary tuberculosis using streptomycin, isoniazid and PAS once, twice or 3 times a week].
    el-Fassi el-Fahri M, Burzoni FJ, Durante C, Ceicu A.
    Bull Int Union Tuberc; 1973 Dec 16; 48 Suppl():158-65. PubMed ID: 4611550
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.